Sunitinib en
p
TNEs
G1/G2
Raymond E, et al. N Eng J Med 2011
Vinik
et al
. Presented at ASCO 2012
ITT population
Sunitinib (N=86)
Placebo (N=85)
BICR assessed
0 5 10 15 20
25
1.0
0.8
0.6
0.4
0.2
0
Time (months)
Median PFS: 12.6 months (95% CI 11.1, 20.6)
Median PFS: 5.8 months (95% CI 3.8, 7.2)
HR 0.32
(95% CI 0.18, 0.55)
P
=0.000015
Complete imaging scan sets
collected for 160/171 patients
(94%)
HR 0.42
(95% CI 0.26, 0.66)
P=
0.000118
0
20
40
60
80
100
Median PFS: 11.4 months (95% CI 7.4, 19.8)
Median PFS: 5.5 months (95% CI 3.6, 7.4)
Time (months)
Investigator assessed
0
25
5
10
15
20
“Beneficio Significativo en SLP”
